telisotuzumab
telisotuzumab: sourced relationships with 1 company · 3 clinical trials tracked · 1 FDA decision.
telisotuzumab evidence translation
What we can confirm
1 FDA record · 3 tracked trials
What it means
What to watch
Prepared research question
How could telisotuzumab → ABBV affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| AbbVie Inc. (ABBV) Reported 2025-05-14 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (3)
Expanded Access to Telisotuzumab Vedotin
A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Primary endpoint: Percentage of Participants with Treatment-Emergent Adverse Events (AE)s (Any-grade and Grade >= 2)
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Primary endpoint: Progression-Free Survival (PFS) per Blinded Independent Central Review (BICR)
Frequently asked questions
Which companies have sourced relationships with telisotuzumab?
telisotuzumab has dated SEC/FDA relationship records for AbbVie Inc..
How many clinical trials involve telisotuzumab?
BioSniper tracks 3 clinical trials involving telisotuzumab.
What is telisotuzumab's latest FDA decision?
The most recent tracked FDA decision for telisotuzumab is Approval, dated May 14, 2025.